Directory
Cristina Gonzalez Mingot

Cristina Gonzalez Mingot

973 70 52 00
cgonzalezm.lleida.ics(ELIMINAR)@gencat.cat

Groups

Publications

  • González-Mingot C.; Gil-Sánchez A.; Begué-Gómez R.; López-Ortega R.; Luis B.R.

    Ischemic encephalopathic debut of CADASIL, a case report: It is better to be safe than sorry

    NEUROLOGIA -. .

    [doi:10.1016/j.nrl.2023.02.002]

  • Gil-Sánchez A.; Gonzalo H.; Canudes M.; Nogueras L.; González-Mingot C.; Valcheva P.; Torres P.; Serrano J.C.; Peralta S.; Solana M.J.; Brieva L.

    Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?

    PHARMACEUTICALS 17 -. .

    [doi:10.3390/ph17040459]

  • Gil-Perotin, S; Reddam, S; González-Mingot, C; Gil-Sánchez, A; González-Suarez, I; Peralta, S; Escrivá, P; Barea-Moya, L; Sánchez-Sánchez, B

    Reliability, validity and distribution of the Spanish female sexual function index in women with relapsing multiple sclerosis

    BMC WOMENS HEALTH 23 -. .

    [doi:10.1186/s12905-023-02811-4]

  • Sancho--Saldaña, A; Gil-Sánchez, A; González-Mingot, C; Peralta, S; Solana, MJ; Torres, P; Juanes, A; Quibus, L; Ruiz, E; Sanpedro, E; Quirant-Sánchez, B; Martínez-Cáceres, E; Tello, CR; Presas-Rodríguez, S; Rubio, SG; Baron, BP; Ramio-Torrenta, L; Sotoca, J; González-Suarez, I; Eichau, S; Prieto-Gonzalez, JM; Quilez, MRB; Sabin-Muñoz, J; Sánchez-López, AJ; Calatayud, GL; Calles, C; Sempere, AP; Garces, M; Carmona, O; Moral, E; Hervas, JV; Blanco, Y; Sola-Valls, N; Lara, NT; Forero, L; Brieva, L

    Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12237243]

  • Mingot, CG; Lasaosa, SS; Campas, LC; Canaval, LC; Sánchez, AG; Ruiz, LB; Alonso, MCM; Moncusi, SP; Marsal, JV; Carner, SC; García, FP

    Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study

    SCIENTIFIC REPORTS 13 19416-19416. .

    [doi:10.1038/s41598-023-44522-8]

  • Vicente-Pascual, M; Quilez, A; Gil, MP; Gonzalez-Mingot, C; Vazquez-Justes, D; Mauri-Capdevila, G; Sanahuja, J; Garcia-Vazquez, C; Purroy, F

    The influence of organisational management on door-to-needle times for fibrinolytic treatment

    NEUROLOGIA 38 313-318. .

    [doi:10.1016/j.nrl.2020.10.014]

  • González-Mingot, C; Miana-Mena, FJ; Iñarrea, PJ; Iñiguez, C; Capablo, JL; Osta, R; Gil-Sánchez, A; Brieva, L; Larrodé, P

    Mitochondrial Aconitase Enzymatic Activity: A Potential Long-Term Survival Biomarker in the Blood of ALS Patients

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12103560]

  • Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L

    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

    JOURNAL OF NEUROLOGY 270 1-12. .

    [doi:10.1007/s00415-023-11575-8]

  • Gil-Sanchez A; Canudes M; Valcheva P; Nogueras L; González-Mingot C; Hervás JV; Peralta S; Solana MJ; Brieva L

    Effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis and depression: a case series study.

    CNS & Neurological Disorders-Drug Targets 23 395-401. .

    [doi:10.2174/1871527322666230321093133]

  • Lleixà C; Caballero-Ávila M; Pascual-Goñi E; Martín-Aguilar L; Vidal N; Tejada C; Valdés-Hevia E; Zárate E; Vesperinas A; Collet R; Franco-Leyva T; Martínez-Martínez L; Moga E; Cortés-Vicente E; Rojas-García R; Gómez-Anson B; Gil A; González-Mingot C; Brieva L; Martínez-Yélamos S; Querol L

    Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis.

    Brain Communications 5 -. .

    [doi:10.1093/braincomms/fcad109]

  • González-Mingot, C; Gil-Sánchez, A; Canudes-Solans, M; Peralta-Moncusi, S; Solana-Moga, MJ; Brieva-Ruiz, L

    Preventive treatment can reverse cognitive impairment in chronic migraine

    JOURNAL OF HEADACHE AND PAIN 23 -. .

    [doi:10.1186/s10194-022-01486-w]

  • Gonzalez-Mingot, C; Lopez-Ortega, R; Brieva-Ruiz, L

    The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2

    NEUROLOGICAL SCIENCES 43 5099-5101. .

    [doi:10.1007/s10072-022-06144-2]

Projects

  • Humanised mouse models to study ATG4B cryptic exon involvement in ALS pathogenesis and its potential as disease biomarker (Hum4ALS)
  • Desregulacion de TDP-43,eje clave en la ELA: Caracterización de firmas lipidómicas, transcriptómicas y autofágicas en muestras específicas de pacientes para biomarcadores y reposicionamiento
  • The Prognostic Value of Cholesterol Esters in the Progression of Multiple Sclerosis” (PROCOLEM)
  • Metabolismo lipidico intracelular, procesamiento de ARNm y estrés celular en la encrucijada de la fisiopatología de la esclerosis lateral amiotrófica
  • BIOMARCADORES DE ESTRES OXIDATIVO Y DISFUNCION ENDOTELIAL EN MIGRAÑA
  • PREDICTUS-USE OF SYSTEM BIOLOGY TO PREDICT AND DIAGNOSE TRANSITORY ISCHEMIA AND ISCHEMIC TOLERANCE
  • Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients